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Shwachman Diamond 
Syndrome: an emergency 
challenge
ABSTRACT
Shwachman Diamond Syndrome is a rare congenital disorder characterized by pancreatic insufficiency, bone marrow 
dysfunction and skeletal abnormalities. No specific test is available for a definitive diagnosis for SDS. In the presence of clinical 
features of SDS, pancreatic insufficiency should be tested for or lipomatosis radiologically demonstrated. New directions might 
be found in genetic analysis. Sometimes, a life-threatening event may be the first clinical manifestation of the syndrome.
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Shwachman Diamond 
Syndrome: a diagnostic 
challenge.
Shwachman Diamond syndrome (SDS) 
is a congenital disorder, first described 
in 1964 in five patients showing exoc-
rine pancreatic insufficiency and leuco-
penia. (1) 
Although SDS is a rare disorder, it is 
the most common cause of pancreatic 
insufficiency in children next to cystic 
fibrosis and probably the third most 
common inherited bone marrow failure 
syndrome after Fanconi’s anemia and 
Diamond-Blackfan anemia.
An autosomal recessive mode of 
inheritance has been described.
Up to December 2000, more than 300 
cases of SDS had been reported in the 
literature. (2)
Clinical features
SDS usually manifests itself in infancy 
with multisystemic abnormalities includ-
ing exocrine pancreatic insufficiency, 
hematological and skeletal abnor-
malities. The clinical phenotype of 
SDS is extremely heterogeneous. (3,4) 
No unifying pathogenetic mechanism 
has yet been shown to be responsible 
for SDS, although new insights into 
molecular, genetic and cellular basis 
of this rare disease have recently been 
described. (3)
Pancreatic insufficiency. Histological 
analysis of the pancreas shows pre-
served ducts and paucity of acini with 
fatty replacement in the gland. More 
than 98% of the exocrine acinar capacity 
of the pancreas must be lost before 
the clinical symptoms of pancreatic 
insufficiency appear. Steatorrhea is 
noted in the first 6 months of life in 
about 50% of affected children and 
increases to 90% by the age of one. (5) 
Steatorrhea and malabsorption might 
lead to malnutrition and fat-soluble 
vitamin deficiency (A, D, E, K). (4) 
Hematological abnormalities. Inter-
mittent neutropenia is the most common 
hematological finding in SDS, occurring 
in 88-100% of patients and it can be 
persistently or intermittently severe, with 
a neutrophil count of <0.5x109/L. (6) 
The neutrophils in patients affected with 
SDS may have impaired mobility and 
defects in migration or chemotaxis. (5) 
Alterations in neutrophil cytoskeletal/
microtubular integrity and function may 
play a significant role in causing the 
defective chemotaxis. 
Therefore, more of the bone marrow 
cellular elements can be involved. Hema-
tological manifestations other than neu-
tropenia include anemia, raised fetal 
hemoglobin levels, thrombocytopenia 
and aplastic anemia. Anemia is the 
second most common cytopenia in 
SDS, recorded in up to 80% of patients. 
It is usually mild and normochromic-
normocytic with a low reticulocyte count. 
(2) Fetal hemoglobin was increased in 
80% of patients. (7)
Many patients develop a mild and 
clinically insignificant thrombocyto-
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penia, defined by a platelet count < 
150x109/L.
Pancytopenia occurs in 10-65% of 
patients. Both anemia and thrombo-
cytopenia are usually mild to moderate 
in these cases but neutropenia tends 
to be severe. Trilineage cytopenia is 
associated with a poor prognosis, that 
is, a higher probability of developing 
symptomatic severe aplasia. (8) 
Hemopoiesis is probably affected by 
defects in the marrow-stromal support 
structure. (2)
As with other constitutional bone 
marrow failure syndromes, retrospective 
studies suggested a high propensity 
for malignant transformation into 
myelodysplast ic syndromes and 
acute myeloid leukemia (25-33% 
of the patients). The detection of 
cytogenetic abnormalities in the bone 
marrow is a marker of clonal evolution 
and malignant transformation. (2) The 
isochromosome 7q (i7q) was found 
with malignant myeloid transformation 
in 25% of SDS patients. (2,9,10)
Skeletal abnormalities. The musculo-
skeletal system is the most commonly 
affected organ after the hematopoietic 
and pancreatic systems; more than 
half of SDS patients have metaphyseal 
dysostoses, which usually involves the 
femoral head. Radiographs may detect 
these alterations after 12 months of 
age. Approximately 30-50% of patients 
show thoracic cage defects, including 
shortened ribs with flared ends and 
chostocondral thickening. (11) Other 
skeletal problems include syndactyly, 
clinodactyly, supernumerary thumbs, 
kyphosis and scoliosis. (12) Significant 
osteoporosis and osteomalacia are 
often observed, most likely due to a 
decrease in vitamin D and vitamin K 
absorption, which result in a high risk 
of pathological fractures. (11)
Immune dysfunction. Patients with SDS 
experience recurrent viral, bacterial and 
fungal infections, including otitis media, 
bronchopneumonia, osteomyelitis, 
skin infection and septicemia. The 
quantitative and qualitative defects in 
SDS neutrophils contribute to these 
infections. Various defects in B and T 
cells have been reported, both quanti-
tative (low IgG levels, low percentage 
of circulating B lymphocytes) and 
qualitative (decreased in vitro lympho-
cyte proliferation, lack of specific anti-
body production). (13)
Other involvement. Failure to thrive is 
commonly observed in patients affected 
with SDS and various factors may 
contribute to this condition, including 
malabsorption, recurrent infections 
and metaphyseal dysostoses. Birth 
weight is often normal, but more than 
50% of patients are still below the 3rd 
percentile for height when they are 
one year old. (8) All patients exhibit 
delayed bone age and delayed puberty. 
Increased risk of caries, mucositis and 
periodontal infections, dental dysplasia 
and delayed dentition of permanent 
teeth are frequently seen. (14)
Hepatomegaly and raised liver enzymes 
are observed in 50-75%, especially in 
young children. (2)
Severe eczema is often seen at presen-
tation. (15)
Recent studies suggest that cognitive 
and attention difficulties are experienced 
by a large number of affected children. 
(16)
Diagnosis
The clinical phenotype of SDS is extre-
mely heterogeneous showing a wide 
range of abnormalities and symptoms. 
At present, no specific biochemical or 
genetic test is available for a definitive 
diagnosis for SDS. Based on current 
knowledge of the SDS phenotype, 
the diagnosis requires evidence 
of exocrine pancreatic dysfunction 
and characteristic hematological 
abnormalities. Short stature, skeletal 
abnormal i t ies,  hepatomegaly or 
biochemical abnormalities of the liver 
are supportive findings of the diagnosis. 
Clinical diagnostic criteria used by Dror 
and Freedman are listed in table 1. (2)
Therefore, SDS must be suspected when 
neutropenia and recurrent infections are 
present, in all children with delayed growth, 
short stature, skeletal abnormalities or 
steatorrhea.
The recognition of pancreatic dys-
function has been regarded as an 
essential part of the diagnosis of SDS. 
Typically, exocrine enzyme secretion is 
diminished. The function of the exocrine 
pancreas is difficult to assess because 
of its anatomical inaccessibility and large 
reserve capacity. The “gold standard”, 
the direct pancreatic stimulation test 
provides quantitative and accurate 
measures of pancreatic function but 
is not widely used in clinical practice 
because of its complexity, cost and 
invasiveness. Pancreatic insufficiency is 
assessed by the absence or decrease 
of trypsin, lipase and amylase activity 
in pancreatic fluid, sampled through a 
nasogastric tube, from less than 2% to 
approximately 10-14% of the reference 
range after a quantitative stimulation 
Table 1: Diagnostic criteria for SDS.
Exocrine pancreatic dysfunction (at least one of the following):
•Abnormal quantitative pancreatic stimulation test.
•Serum cationic trypsinogen below the normal range.
•Abnormal 72 hour fecal fat analysis plus evidence of pancreatic 
lipomatosis by ultrasonographic examination or CT scan.
AND Hematological abnormalities (at least one of the following):
•Chronic (on two occasions at least 6 weeks apart) single lineage or 
multilineage cytopenia with bone marrow findings consistent with a 
productive defect:
- neutrophil < 1.5x109/l





test with intravenous secretin and 
cholecystokinin. (2)
In SDS, low serum immunoreactive 
trypsinogen values are based on re-
duced acinar enzyme production, 
because pancreatic failure is due to 
hypoplasia. On the other hand, in cystic 
fibrosis, the serum immunoreactive 
trypsinogen level is high because of the 
underlying pathophysiological features 
affecting the pancreatic duct and the 
inability to secrete digestive enzymes 
into the duodenal lumen. 
In some patients with SDS, the exocrine 
pancreatic enzyme production is so low 
that the patient clinically manifests with 
steatorrhea and has abnormal 72-hour 
fecal fat studies. However, the absence 
of steatorrhea does not exclude the 
diagnosis of SDS. (8)
Syndromes that can manifest pan-
creatic pathology include: Beckwith 
Wiedemann syndrome, von Hippel-
Lindau disease, autosomal dominant 
polycystic kidney disease and Pearson 
disease (pancreatic insufficiency, 
neutropenia, marrow ring sideroblasts 
and vacuolated erythroid and myeloid 
precursors). Pancreatic abnormalities, 
associated with fatty replacement of 
the gland, can be found also in cystic 
fibrosis, Cushing syndrome, obesity or 
Johanson Blizzard Syndrome. (17)
A negative sweat test allows us to rule 
out the diagnosis of cystic fibrosis.
Histological analysis of the pancreas 
shows preserved ducts and paucity 
of acinis with fatty replacement in the 
gland, a feature that may be delineated 
by appropriate radiological imaging 
studies.
Pancreatic lipomatosis is a radiological 
feature of SDS as well as of the very 
rare Johanson Blizzard Syndrome but 
other clinical abnormalities (facial and 
especially urogenital) should help to 
differentiate the two entities.
Diagnostic imaging plays a mayor role 
in the evaluation of the pancreas in 
infants and children. (18)
Ultrasonography represents the less 
invasive radiological technique for 
investigating the pancreatic gland. The 
pancreas, in SDS affected patients, 
appears of normal size with increased 
echogenicity of the silhouette. In 
contrast, the size of the pancreas in 
patients with cystic fibrosis usually is 
decreased. However, ultrasonography 
might be inadequate as the size of the 
gland cannot be easily measured with 
accuracy for its hyperechogenicity or for 
the presence of abdominal meteorism 
due to malabsorption.
CT and MRI reveal lipomatosis of the 
pancreas with greater accuracy but CT 
has the major disadvantage of using 
ionizing radiation.
MRI is an imaging method that allows 
correlation of the tissue specificity of an 
organ to its radiological representation, 
especially in the presence of fat, which 
is easily recognized in T1 and T2 
weighted sequences. (19)
Therefore, when pancreatic lipomatosis 
assessed by MRI, or CT, is associated 
with clinical characteristics which are 
suggestive of SDS, diagnosis of SDS 
should be strongly considered. 
Genetic analysis
In 2002, researchers from Toronto 
cloned the gene responsible for SDS 
(SBDS) and identified mutations in-
volved in the disease. The gene has 
been mapped to chromosome 7q11. 
Molecular diagnostic testing is now 
available. (5) The SBDS gene mutations 
have been detected in most (80%), 
but not all patients with SDS. (20) This 
suggests that SDS is a genetically 
heterogeneous disorder. The SBDS 
gene has an adjacent pseudogene (an 
identical but nonfunctional gene) on 
7q11. The majority of mutations are 
caused by a recombination during 
meiosis between SBDS and its highly 
homologous pseudogene, so that 
some parts of the pseudogene are 
incorporated into the normal SBDS gene. 
The altered SBDS gene received non 
functional parts from the pseudogene, 
which made it dysfunctional. (5)
The function of the SBDS encoded 
protein has not been elucidated. The 
transcript of the normal gene is widely 
expressed in the pancreas, bone marrow 
and leucocytes. Hence, it has been 
postulated that the SDS phenotype may 
result from a defect in RNA process-
ing that disrupts a cellular function 
necessary for hematopoietic, pancreatic 
and skeletal development. (21)
Acute manifestations and 
supportive care
Overwhelming sepsis is a well re-
cognized fatal complication of this 
disorder, particularly early in life. (2) In 
case of fever and severe neutropenia, 
bacterial cultures (from blood, urine, 
throat) should be performed because 
of the increased risk of sepsis from the 
neutrophil migrational defect ob-served 
in the disease. In addition, patients 
should receive prompt therapy based 
on intravenous antibiotics with a broad 
spectrum coverage until the infection 
clears up. Granulocyte colony stimulating 
factor (G-CSF) may be prescribed 
and patients would probably benefit 
during acute infections. (2) The most 
likely bacterial pathogens in SDS are 
Staphylococcus Aureus, Haemophilus 
influenzae and Pseudomonas species. 
(22)
Fatal bleeding, in patients suffering from 
moderate to severe thrombocytopenia, 
has been reported. (9) Platelet and/or 
plasma transfusions and parenteral 
vitamin K may be necessary to diminish 
the risk of bleeding. Although patients 
with anemia and thrombocytopenia may 
be supported by red cell and platelet 
transfusions, very severe neutropenia 
(ANC<200/μL) remains an adverse 
prognostic factor as it is associated 
with a high mortality rate and risk of life-
threatening infections. (23)
Natural history 
Prognosis is uncertain. Since SDS 
has been described relatively recently, 
limited data are available regarding 
follow up in these affected patients. 
Death usually occurs from overwhelming 
sepsis or malignancies. Alter et al 
(1997) reported a median survival age 
older than 35 years for all patients with 
SDS. For those patients whose course 
is complicated by aplastic anemia, 
the median survival age is 24 years, 
while those patients whose course is 
complicated by leukemia have a median 
survival age of 10 years. (24) 
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Management
Management of children with SDS 
should be multidisciplinary. The child 
should be primarily under the care of 
a local general pediatrician. Long term 
follow up requires collaboration bet-
ween pediatric gastroenterologists and 
hematologists. A significant proportion 
of patients with SDS require pancreatic 
enzymes. The dosage should be 
adapted to the severity of the symptoms, 
such as steatorrhea, abdominal pain 
and growth parameters. 
Depending on the evolution of hemato-
logical abnormalities, a full blood count 
must be performed every 3-6 months or 
more frequently if symptoms require. An 
annual bone marrow biopsy has to be 
performed for surveillance of the acquisition 
of cytogenetic abnormalities. (5)
Complications of the disease, such as 
sepsis or hematological symptomatic 
abnormalities, might require admission 
to an Intensive Care Unit. 
Conclusion
Any child with steatorrhea and poor 
weight gain, after excluding cystic 
fibrosis, should be investigated for 
exocrine pancreatic insufficiency. The 
assessment of pancreatic dysfunction 
or the less invasive radiological de-
monstration of fatty replacement 
has primary importance. Diagnostic 
criteria should help in establishing the 
diagnosis. Other clinical abnormalities 
support the suspected condition. A 
specific diag-nostic test for SDS is 
not available and definitive diagnosis 
still represents a challenge. Genetic 
analysis might be the future direction. 
Clinicians should take into account 
that life-threatening events may be 
the first clinical manifestation of the 
disease.
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